FDA approves Alnylam's first-ever drug for rare kidney disease

The Cambridge company's gene-silencing drug, for a rare disorder called primary hyperoxaluria type 1, had been developed under the generic name lumasiran but will be sold under the commercial brand name Oxlumo.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.